This work was supported by the Canadian Institutes of Health Research (funding reference number: 154862), the Montreal Heart Institute Foundation and the Universite´ de Montre´ al Beaulieu-Saucier Chair in Pharmacogenomics. S de Denus reports grants outside the submitted work from AstraZeneca and RMS/Dalcor. A patent pertaining to pharmacogenomics-guided CETP inhibition was granted, and J-C Tardif andM-P Dube´ arementioned as authors.M-P Dube´ has aminor equity interest in DalCor.M-P Dube´ has research support (access to samples and data) from AstraZeneca, Pfizer, Servier, Sanofi and GlaxoSmithKline. J-C Tardif has received research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Merck, Novartis, Pfizer, RegenXBio and Sanofi and honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, and Pendopharm and Pfizer and has minor equity interest in DalCor Pharmaceuticals and authorship of patents on the use of colchicine after myocardial infarction and on pharmacogenomics-guided CETP inhibition. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.